Illumina, Inc. $ILMN Shares Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.4% during the second quarter, Holdings Channel.com reports. The fund owned 69,845 shares of the life sciences company’s stock after purchasing an additional 8,800 shares during the period. KLP Kapitalforvaltning AS’s holdings in Illumina were worth $6,664,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Diversified Trust Co acquired a new position in shares of Illumina during the 1st quarter valued at $355,000. Bourgeon Capital Management LLC grew its holdings in Illumina by 76.4% during the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after acquiring an additional 61,468 shares during the period. GC Wealth Management RIA LLC acquired a new position in Illumina during the second quarter worth about $2,289,000. State of Alaska Department of Revenue grew its holdings in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock worth $1,469,000 after acquiring an additional 445 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in Illumina by 171.2% during the first quarter. Acadian Asset Management LLC now owns 32,921 shares of the life sciences company’s stock worth $2,608,000 after acquiring an additional 20,784 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 2.7%

NASDAQ ILMN opened at $93.86 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market cap of $14.43 billion, a price-to-earnings ratio of 11.88, a PEG ratio of 2.33 and a beta of 1.40. The firm’s 50 day moving average price is $98.33 and its two-hundred day moving average price is $90.21.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the company posted $0.36 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ILMN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research note on Wednesday. Stephens set a $110.00 price target on shares of Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Citigroup cut Illumina from a “hold” rating to a “strong sell” rating and decreased their target price for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Finally, Daiwa Capital Markets cut Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $123.56.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.